Foundry Healthcare ChTax Factor ETF
ETF Foundry Research (hypothetical) · rebalanced monthly
Every other metric on this page is the long-shortstrategy, which needs a short book. This fund is the long leg alone, so these are the figures for what it actually holds. The bottom-bucket number is that basket’s own return — not short P&L.
Hypothetical growth of $1 — long-short backtest
Gross of the placeholder expense ratio and trading costs · not investor results
Holdings
Every constituent of the long leg — sort, search or filter by sector
| Ticker | Company | Sector | Market cap | Weight |
|---|---|---|---|---|
1LLY | ELI LILLY & CO | Healthcare | $1.11T | 34.86% |
2ABBV | ABBVIE INC | Healthcare | $449.63B | 14.11% |
3AMGN | AMGEN INC | Healthcare | $197.69B | 6.21% |
4ABT | ABBOTT LABORATORIES | Healthcare | $175.37B | 5.50% |
5GILD | GILEAD SCIENCES INC | Healthcare | $166.72B | 5.23% |
6BMY | BRISTOL MYERS SQUIBB CO | Healthcare | $124.04B | 3.89% |
7VRTX | VERTEX PHARMACEUTICALS INC | Healthcare | $123.26B | 3.87% |
8SYK | STRYKER CORP | Healthcare | $122.63B | 3.85% |
9ISRG | INTUITIVE SURGICAL INC | Healthcare | $122.33B | 3.84% |
10REGN | REGENERON PHARMACEUTICALS INC | Healthcare | $70.94B | 2.23% |
11IDXX | IDEXX LABORATORIES INC | Healthcare | $44.76B | 1.41% |
12ALNY | ALNYLAM PHARMACEUTICALS INC | Healthcare | $35.71B | 1.12% |
13VEEV | VEEVA SYSTEMS INC | Healthcare | $31.74B | 1.00% |
14DXCM | DEXCOM INC | Healthcare | $29.58B | 0.93% |
15RMD | RESMED INC | Healthcare | $28.86B | 0.91% |
16ILMN | ILLUMINA INC | Healthcare | $28.24B | 0.89% |
17ROIV | ROIVANT SCIENCES LTD | Healthcare | $24.82B | 0.78% |
18MRNA | MODERNA INC | Healthcare | $24.53B | 0.77% |
19STE | STERIS PLC | Healthcare | $21.26B | 0.67% |
20NBIX | NEUROCRINE BIOSCIENCES INC | Healthcare | $17.18B | 0.54% |
21MEDP | MEDPACE HOLDINGS INC | Healthcare | $15.36B | 0.48% |
22SOLV | SOLVENTUM CORP | Healthcare | $14.08B | 0.44% |
23BTSG | BRIGHTSPRING HEALTH SERVICES INC | Healthcare | $13.71B | 0.43% |
24BAX | BAXTER INTERNATIONAL INC | Healthcare | $11.68B | 0.37% |
25PODD | INSULET CORP | Healthcare | $11.36B | 0.36% |
26EHC | ENCOMPASS HEALTH CORP | Healthcare | $11.13B | 0.35% |
27ARWR | ARROWHEAD PHARMACEUTICALS INC | Healthcare | $10.47B | 0.33% |
28TEM | TEMPUS AI INC | Healthcare | $9.42B | 0.30% |
29HALO | HALOZYME THERAPEUTICS INC | Healthcare | $9.23B | 0.29% |
30UHS | UNIVERSAL HEALTH SERVICES INC | Healthcare | $9.15B | 0.29% |
31HQY | HEALTHEQUITY INC | Healthcare | $8.17B | 0.26% |
32LQDA | LIQUIDIA CORP | Healthcare | $7.11B | 0.22% |
33LGND | LIGAND PHARMACEUTICALS INC | Healthcare | $6.08B | 0.19% |
34BLCO | BAUSCH & LOMB CORP | Healthcare | $5.80B | 0.18% |
35SHC | SOTERA HEALTH CO | Healthcare | $5.06B | 0.16% |
36KNSA | KINIKSA PHARMACEUTICALS INTERNATIONAL PLC | Healthcare | $4.92B | 0.15% |
37LFST | LIFESTANCE HEALTH GROUP INC | Healthcare | $4.49B | 0.14% |
38MMSI | MERIT MEDICAL SYSTEMS INC | Healthcare | $4.41B | 0.14% |
39NVST | ENVISTA HOLDINGS CORP | Healthcare | $4.35B | 0.14% |
40DOCS | DOXIMITY INC | Healthcare | $3.94B | 0.12% |
41CPRX | CATALYST PHARMACEUTICALS INC | Healthcare | $3.85B | 0.12% |
42OGN | ORGANON & CO | Healthcare | $3.55B | 0.11% |
43GRAL | GRAIL INC | Healthcare | $3.12B | 0.10% |
44XRAY | DENTSPLY SIRONA INC | Healthcare | $2.81B | 0.09% |
45TARS | TARSUS PHARMACEUTICALS INC | Healthcare | $2.58B | 0.08% |
46GRDN | GUARDIAN PHARMACY SERVICES INC | Healthcare | $2.57B | 0.08% |
47QURE | UNIQURE NV | Healthcare | $2.54B | 0.08% |
48LMAT | LEMAITRE VASCULAR INC | Healthcare | $2.32B | 0.07% |
49NEOG | NEOGEN CORP | Healthcare | $2.24B | 0.07% |
50MD | PEDIATRIX MEDICAL GROUP INC | Healthcare | $2.15B | 0.07% |
51ADMA | ADMA BIOLOGICS INC | Healthcare | $2.02B | 0.06% |
52ABCL | ABCELLERA BIOLOGICS INC | Healthcare | $1.97B | 0.06% |
53HRMY | HARMONY BIOSCIENCES HOLDINGS INC | Healthcare | $1.96B | 0.06% |
54ANIP | ANI PHARMACEUTICALS INC | Healthcare | $1.80B | 0.06% |
55IMCR | IMMUNOCORE HOLDINGS PLC | Healthcare | $1.78B | 0.06% |
56HROW | HARROW INC | Healthcare | $1.74B | 0.05% |
57HCSG | HEALTHCARE SERVICES GROUP INC | Healthcare | $1.74B | 0.05% |
58INVA | INNOVIVA INC | Healthcare | $1.60B | 0.05% |
59XERS | XERIS BIOPHARMA HOLDINGS INC | Healthcare | $1.52B | 0.05% |
60PNTG | PENNANT GROUP INC | Healthcare | $1.46B | 0.05% |
61AMN | AMN HEALTHCARE SERVICES INC | Healthcare | $1.36B | 0.04% |
62PAHC | PHIBRO ANIMAL HEALTH CORP | Healthcare | $1.35B | 0.04% |
63IRMD | IRADIMED CORP | Healthcare | $1.24B | 0.04% |
64AORT | ARTIVION INC | Healthcare | $1.22B | 0.04% |
65COLL | COLLEGIUM PHARMACEUTICAL INC | Healthcare | $1.17B | 0.04% |
66AVNS | AVANOS MEDICAL INC | Healthcare | $1.17B | 0.04% |
67NUTX | NUTEX HEALTH INC | Healthcare | $1.12B | 0.04% |
68CERT | CERTARA INC | Healthcare | $1.08B | 0.03% |
69BVS | BIOVENTUS INC | Healthcare | $1.01B | 0.03% |
70FBRX | FORTE BIOSCIENCES INC | Healthcare | $1.00B | 0.03% |
71TBPH | THERAVANCE BIOPHARMA INC | Healthcare | $873M | 0.03% |
72OMER | OMEROS CORP | Healthcare | $701M | 0.02% |
73CRMD | CORMEDIX INC | Healthcare | $661M | 0.02% |
74TCMD | TACTILE SYSTEMS TECHNOLOGY INC | Healthcare | $648M | 0.02% |
75MYGN | MYRIAD GENETICS INC | Healthcare | $584M | 0.02% |
76CTEV | CLARITEV CORP | Healthcare | $518M | 0.02% |
77XOMA | XOMA ROYALTY CORP | Healthcare | $504M | 0.02% |
78VMD | VIEMED HEALTHCARE INC | Healthcare | $466M | 0.01% |
79PRTA | PROTHENA CORP PUBLIC LTD CO | Healthcare | $453M | 0.01% |
80DCTH | DELCATH SYSTEMS INC | Healthcare | $442M | 0.01% |
81PBYI | PUMA BIOTECHNOLOGY INC | Healthcare | $434M | 0.01% |
82CCRN | CROSS COUNTRY HEALTHCARE INC | Healthcare | $428M | 0.01% |
83CBIO | CRESCENT BIOPHARMA INC | Healthcare | $407M | 0.01% |
84ENTA | ENANTA PHARMACEUTICALS INC | Healthcare | $400M | 0.01% |
85SLP | SIMULATIONS PLUS INC | Healthcare | $369M | 0.01% |
86ELMD | ELECTROMED INC | Healthcare | $349M | 0.01% |
87VNDA | VANDA PHARMACEUTICALS INC | Healthcare | $327M | 0.01% |
88PDEX | PRO DEX INC | Healthcare | $183M | 0.01% |
89CUE | CUE BIOPHARMA INC | Healthcare | $126M | 0.00% |
90OPRX | OPTIMIZERX CORP | Healthcare | $126M | 0.00% |
91FRMM | FORUM MARKETS INC | Healthcare | $83M | 0.00% |
Full long-leg book as of July 2026 · cap-weighted · total market cap $3.19T. Hypothetical model holdings — not a registered fund’s portfolio.
Sector Breakdown
Portfolio Style
Size × value map of the long-leg book
Share of long-leg capital by market cap × book-to-market, using terciles of the 499-name universe at July 2026. Rows: Large ≥ $3.6B, Small < $964M. Columns: Value ≥ 0.67, Growth < 0.37 B/M. The dot marks the capital-weighted centroid of the book — 99% toward Large, 74% toward Growth. +1% unclassified (9 missing size/value). Hypothetical holdings — descriptive, not realized P&L.
Capital-weighted centroid of the long leg, December 1998 → July 2026; the right-hand end is the same value as the box’s dot. 91 names now. The faded start covers early months with a much thinner universe. Hypothetical holdings — descriptive, not P&L.
Constraint checks
How this book measures against the concentration and liquidity rules — as implemented here
These are UNCONSTRAINED factor sleeves: the construction pipeline sorts on a signal and cap-weights the top bucket, applying no issuer cap, no industry cap and no liquidity screen beyond the universe filter. A failing test therefore reports a constraint that was never applied during construction — it is not a defect in the strategy and not an error in the data. The same signal can be solved subject to these constraints.
7 independent checks plus 1 arithmetically implied by another check (RIC / IRC 851(b)(3)(A) 50% bucket), which is reported separately so the tally cannot overstate scrutiny.
1 of 7 checks could not be tested. Those are neither passes nor failures — they are gaps in what the data can answer, and they are excluded from the passed count above rather than folded into it.
With respect to 75% of total assets, no more than 5% may be invested in the securities of any one issuer.
Required>= 75.0%Actual59.1%Margin-15.9%No more than 25% of total assets may be invested in the securities of any one issuer.
Required<= 25.0%Actual34.9%Margin-9.9%Days required to liquidate the largest position at 20% of one day's dollar volume.
Required<= 7.0 daysActualunboundedMargin—
Engineering approximation of the cited rules for a DRAFT / HYPOTHETICAL model portfolio that is not a registered fund. This reports whether the portfolio passes the stated test AS IMPLEMENTED HERE; it is not a compliance opinion and is not a statement that any fund is compliant. Real filings need securities counsel.
No verdict sits within 1.0pp of its limit.
Data version — panel=20260719T025334 rows=2239262 asof=202607 issuers=20260719T014536 rates=20260804T224700
Measured on the 2026-07 formation date across 91 holdings (cap-weighted). A different formation date can produce different verdicts.
Derivatives risk (Rule 18f-4)
Whether this long-only book is subject to the VaR tests at all
This assessment describes the long-only book this fund holds — the top bucket only.
This fund QUALIFIES for the limited-derivatives-user exception, so it is excepted from the VaR tests; the ratio below is informational, not the operative limit.
Rule 18f-4(c)(4): a fund whose derivatives exposure (gross notional, including the value of assets sold short) is <= 10% of net assets is excepted from the VaR tests and the full derivatives risk management program.
No confidence interval: this follows from portfolio construction, not from an estimate.
Rule 18f-4(c)(2)(i): fund VaR at 99% over 20 trading days must not exceed 200% of the designated reference portfolio's VaR on the same basis.
Informational — does not governThis fund is excepted from the VaR tests, so the ratio below is context rather than the operative limit. It is shown because it is still a description of the book’s risk, not because it decides anything.
historical method · 331 monthly observations · about 3.3 in the 99% tail · paired percentile bootstrap over months
The estimators differ materially in value but agree on the verdict. Historical and Gaussian fund VaR differ by 15%; both still land on the same side of the 2x limit.
Engineering approximation of SEC Rule 18f-4 for research display. Not a compliance opinion and not a determination that any fund is compliant. Hypothetical model portfolio, not a registered fund.
The research long-short construction behind this factor does not qualify for this exception — a dollar-neutral book counts its full short notional, which is 100% of net assets against a 10% threshold. This product sidesteps that by holding the long leg alone, which is also why the long-leg Sharpe is reported separately throughout the site.
See the long-short verdict on the factor page →Since publication
Did the edge survive the paper coming out?
Split at January of the year after the factor was published. The post-publication stretch IS genuinely out-of-sample relative to the original study -- the predictor was public by then -- so it speaks to whether the effect survived being known. Nothing is fitted here, so this is performance SINCE PUBLICATION, not validation of a model. Note the 'pre' side is our data before publication (our panel starts ~1999), NOT the study's original in-sample period, which usually ran decades earlier; a decay figure compares before-vs-after within our sample and is not a comparison against the published result.
Consistency across eras
Is this record broadly durable, or one regime?
3-year rolling windows, stepping 1 year (26 windows). Dispersion is the spread of window Sharpes — higher means the record depends more on which era you look at.
Rules-based factors fit no parameters, so these windows are not out-of-sample tests and do not validate a fitted model. They show whether the factor's record is consistent across eras or driven by one regime.
Returns
Long leg is what this fund holds — long-short is shown for reference
| Period | Long leg | Long-short |
|---|---|---|
| 1 yearcum. | 36.9% | -2.3% |
| 3 yearsp.a. | 16.1% | 8.5% |
| 5 yearsp.a. | 5.4% | -2.1% |
| 10 yearsp.a. | 10.1% | 0.2% |
| Since inceptionp.a. | 10.0% | -2.0% |
| Year | Long leg | Long-short |
|---|---|---|
| 20267 mo | 8.4% | -13.2% |
| 2025 | 26.8% | 18.8% |
| 2024 | 8.7% | 12.9% |
| 2023 | 4.1% | 12.3% |
| 2022 | -14.9% | -22.1% |
| 2021 | 20.6% | -5.1% |
| 2020 | 14.5% | 5.2% |
| 2019 | 14.9% | -4.1% |
| 2018 | 7.3% | 2.8% |
| 2017 | 24.0% | 0.4% |
| 2016 | -7.7% | -7.2% |
| 2015 | 5.4% | -4.9% |
| 2014 | 29.7% | 1.7% |
| 2013 | 41.4% | -2.2% |
| 2012 | 19.4% | 2.4% |
| 2011 | 14.7% | -1.9% |
| 2010 | 0.8% | -12.6% |
| 2009 | 29.0% | 0.5% |
| 2008 | -13.5% | -4.2% |
| 2007 | 4.9% | -2.0% |
| 2006 | -3.9% | -15.3% |
| 2005 | 13.6% | 3.9% |
| 2004 | 10.8% | 13.8% |
| 2003 | 33.3% | -16.8% |
| 2002 | -27.2% | -5.0% |
| 2001 | -9.2% | -1.0% |
| 2000 | 44.6% | -17.0% |
| 1999 | 13.4% | 21.1% |
Long leg = the top bucket this fund holds; long-short additionally shorts the bottom bucket and is not achievable in a long-only vehicle. Trailing figures run through July 2026: 1 year is a plain cumulative 12-month return (cum.), 3 years and longer are annualised (p.a.). Years marked with a month count are partial. These match the fact sheet’s tables by construction. Hypothetical backtest, gross of the placeholder expense ratio and trading costs — not investor results.
Fund Facts
Methodology
The Foundry Healthcare ChTax Factor ETF tracks a rules-based model that ranks Healthcare common stocks each month by a ChTax signal and holds the top quintile with the highest values. Signals are computed from point-in-time Sharadar fundamentals and total-return prices. The portfolio reconstitutes monthly and is cap-weighted within the long leg.
This is a hypothetical model portfolio for research display only — not a registered fund, not an offer, and not investment advice.
Documents (draft — hypothetical)
Auto-generated from the model’s metrics and current holdings. Every document is labeled DRAFT / hypothetical.
Objective, fees, strategy, and key risks.
Full strategy, model methodology, and risks.
Policies, construction, and governance.
One-page snapshot with top holdings.
Full current constituent list.
DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.